Navigation Links
IASLC welcomes publication of CT screening results from National Lung Screening Trial
Date:6/30/2011

The International Association for the Study of Lung Cancer (IASLC) today welcomed the publication of positive results of the National Lung Screening Trial (NLST).

The NLST study, published today in the New England Journal of Medicine, showed that lung cancer deaths fell by 20% and all-cause mortality fell by 7% when heavy smokers were screened regularly using low-dose spiral computed tomography (CT) compared with standard chest x-ray. The NLST study followed more than 53,000 current and former smokers ages 55-74.

"Lung cancer is the leading cause of cancer death in the world and there has been no effective means of early detection, which is critical to improving outcome because surgery can cure early-stage disease but there are no curative therapies for advanced disease," said IASLC Executive Director Dr. Paul A. Bunn, Jr., M.D. Bunn holds the James Dudley Chair in Cancer Research at the University of Colorado School of Medicine, Division of Medical Oncology.

Experts from around the world will gather in Amsterdam on July 2-3 for an invitation-only Lung Cancer CT Screening Workshop prior to the start of the 14th World Conference on Lung Cancer (WCLC). IASLC will host the WCLC in Amsterdam from July 3-7.

Topics to be discussed at the workshop include recommendations for CT screening implementation and the appropriate workup for screen-detected lung cancers.

A press briefing on CT screening, summarizing the conclusions of the workshop, will be held at 10:00 a.m. Central European Time (Amsterdam) on Monday, July 4. Press materials and an audio webcast of the press briefing will be available on the IASLC website: http://iaslc.org/press-room/wclc-press-releases/

"The publication of the NLST trial is a major turning point in lung cancer, which demonstrates the enormous potential of CT screening as an early detection tool, which, in combination with smoking cessation programs, is likely to have a major impact on lung cancer," said Professor John K. Field, MA, Ph.D., BDS FRCPath, who chairs IASLC's CT Screening Task Force. Field is director of research at the Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine at The University of Liverpool.

Although the NLST results are encouraging, other important trials are under way that will provide critical additional information not only on mortality advantage and cost effectiveness, but also on the clinical management outcomes of lung cancer screening. Different nations will require varying levels of evidence to support the decision to provide national lung cancer screening services.

"It is important to realize that enthusiasm for routine use of these scans should be limited to the population studied -- 30 pack years of smoking and age 55-74 -- and that many issues remain unresolved," Dr. Bunn said. "Among these are the cost-effectiveness of the procedure and the best way to follow small nodules that may or may not be cancer."


'/>"/>

Contact: Renee McGaw
renee.mcgaw@ucdenver.edu
303-641-3534
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. IASLC to help advocacy organizations attend 14th World Conference on Lung Cancer in Amsterdam
2. IASLC launches Staging Atlas in Thoracic Oncology for iPad, iPhone, Android and BlackBerry
3. Diet-to-Go Welcomes 2 Key Philadelphia Fitness Centers as Partners-in-Health
4. Health Connect Partners Welcomes Cardinal Health as Three-Year Title Sponsor
5. Abington Memorial Hospital Welcomes Vakil to Orthopaedic Surgery Division
6. Jewish Board of Family and Childrens Services Welcomes New Board President, Tony Mann
7. Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service
8. Sisters of Charity Health System Welcomes Mark Wiedt to its Business Development Team
9. 2010 Caring Coalition Conference Welcomes Author Gail Sheehy
10. Christopher & Dana Reeve Foundation Welcomes Actor/Writer Danny Arroyo as a Foundation Ambassador
11. MMG Welcomes Ann Kottcamp to Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... (PRWEB) , ... December 02, 2016 , ... ... will give patients better access to nutraceuticals and help doctors more efficiently manage ... patient portal and practice management software platform for Integrative and Functional Medicine. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-Aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold ... certified and experienced Indoor Air Quality Companies in VA, MD and DC, recently completed ... , The new mold law in the district of Columbia is a good ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... documentary on the perils of heroin that was watched live by 1 million ... Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite School ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... Taiwan , Dec. 5, 2016 ... non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... profile of ropeginterferon alfa-2b versus HU AOP ... follow-up trial CONTINUATION-PV to obtain European marketing authorization in the ... data to the FDA as it seeks approval for commercialization ...
(Date:12/4/2016)... --  Pairnomix, LLC, a genetic research company and member ... White House, today announced that findings from its first case ... therapies for a patient with epileptic encephalopathy caused by a ... the 70 th Annual Meeting of the American ... December 2-6, 2016.  Pairnomix, unique process involves creating ...
Breaking Medicine Technology: